NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Joseph P. McGuirk(University of Kansas Medical Center), Saurabh Dahiya(Stanford University), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Cristina Castilla‐Llorente(Institut Gustave Roussy), James Essell(Oncology Hematology Care), Mario Q. Marcondes(Nektar Therapeutics (United States)), John F. DiPersio(Washington University in St. Louis), Mary Tagliaferri(Nektar Therapeutics (United States)), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Christie Fanton(Nektar Therapeutics (United States)), Cameron J. Turtle(The University of Sydney), Heng Xu(Nektar Therapeutics (United States)), Zachary Lee(Nektar Therapeutics (United States)), Yi Liu(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), David B. Miklos(Stanford University), Catherine Diefenbach(NYU Langone Health)
Cited by 3
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816